Ongoing trials with matrix metalloproteinase inhibitors

Bibliography

• PFIZER CORP.: Pfizer discontinues Phase III trials of prinomastat in advanced cancers but continues multiple Phase II trials. Press Release (2000) August 4.
   Google Scholar
• NAGASE H, WOESSNER JF: Matrix metalloproteinases. Biol. Chem. (1999) 274(30:21491–21494.
   Google Scholar
• GOMEZ DE, ALONSO DF, YOSHIJI H, THORGEIRSSON UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J Cell Biol. (1997) 74(2):111–122.
   PubMed Web of Science ®Google Scholar
• GRAMS F, CRIMMIN M, HINNES L et al.: Structure determination and analysis of human neutrophil collagenase complex ed with a hydoxamate inhibitor. Biochemistry (1995) 34:14012–14020.
   PubMed Web of Science ®Google Scholar
• BEATTIE GJ, SMYTH JF: Phase I study of i.p. metallopro-teinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res. (1998) 4:1899–1902.
   Google Scholar
• MACAULAY VM, O'BYRNE KJ, SAUNDERS MP et al: Phase I study of intrapleural batimastat (BB-94), an oral matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. an. Cancer Res. (1999) 5:513–520.
   Web of Science ®Google Scholar
• GALARDY RE, CASSABONE ME, GIESE C et al.: LOW molecular weight inhibitors in corneal ulceration. Ann. NY Acad. Sci. (1994) 732:315–323.
   PubMed Web of Science ®Google Scholar
• BETZ M, HUXLEY P, DAVIES SJ et al.: 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complex ed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur. Biochem. (1997) 247 (1):356–363.
   Google Scholar
• WHITTAKER M, FLOYD CD, BROWN P, GEARING AJH: Design and therapeutic application of matrix metallo-proteinase inhibitors. Chem. Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• •A useful reference giving structures of a wide variety of MMPIs.
   Google Scholar
• MACPHERSON LJ, BAYBURT EK, CAPPARELLI MP et al.: Discovery of CGS 27023A, a non-pep tidic, potent and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med. Chem. (1997) 40 (16):2525–2532.
   PubMed Web of Science ®Google Scholar
• SHALINSKY DR, BREKKEN J, ZOU H et al.: Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. NY Acad. Sci. (1999) 878:236–270.
   PubMed Web of Science ®Google Scholar
• MILLAR AW, BROWN PD, MOORE J et al.: Results of single and repeat dose studies of the oral matrix metallopro-teinase inhibitor marimastat in healthy male volunteers. Br. J Clin. Pharm. (1998) 45:21–26.
   PubMed Web of Science ®Google Scholar
• COLLIER MA, YUEN GJ, BANSAL SK et al.: A Phase I studyof the matrix metalloproteinase (MM1') inhibitor AG3340 given in single doses to healthy volunteers.Proc. Am. Assoc. Cancer Res. (1997) 38:Abstract 1491,221.
   Google Scholar
• SHAH A, SUNDARESAN P, HUMPHREY R et al.: Compara-tive pharmacokinetics (PK) of BAY 12–9566, a metallo-proteinase (MMP) inhibitor, in healthy volunteers and cancer patients. Proc. Am. Assoc. Cancer Res. (1998) 39:Abstract 3547,521.
   Google Scholar
• LEWIS EJ, BISHOP J, BOTTOMLEY KMK et al.: Ro 32-3555,an orally active collagen ase inhibitor, prevents cartilage breakdown in@! vitro and in WYO. Br. J. Pharmacol. (1997) 121:540–546.
   PubMed Web of Science ®Google Scholar
• LEVITT NC, ESKENS F, PROPPER et al.: A Phase I pharma-cokinetic study of CGS27023A, a matrix metalloprote-inase inhibitor. Proc. Am. Soc. Clin. Oncol. (1998) 17:Abstract 823.
   Google Scholar
• HUGHES S: Bayer drug casts shadow over MMP inhibi-tors in cancer. Scrip Daily News Alert (1999):40301.
   Google Scholar
• O'REILLY MS, WIEDERSCHAIN D, STETLER-STEVENSON WG, FOLKMAN J, MOSES MA: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. (1999) 274:29568–29571.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, HAMM J, EISENBERG P et al.: A comparisonbetween gemcitabine and the matrix metalloprote-inase inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19 :Abstract 930,240a
   Google Scholar
• NEMUNAITIS J, POOLE C, PRIMROSE J et al.: Combinedanalysis of studies of the effects of the matrix metallo-proteinase inhibitor marimastat on serum tumour markers in advanced cancer: Selection of a biologi-cally active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1111.
   PubMed Web of Science ®Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor administered orally to patients with advanced lung cancer. J. Clin. Oncol. (1998) 16:2150–2156.
   PubMed Web of Science ®Google Scholar
• ••One of the first descriptions of the musculoskeletal pain andinflammation that constitutes the principal side effect of marimastat.
   Google Scholar
• WILDING G, SMALL E, COLLIER M, DIXON M, PITHAVALAY: A Phase I pharmacokinetic evaluation of the matrix metalloproteinase inhibitor AG-3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:Abstract 1244,323a.
   Google Scholar
• GOEL R, HIRTE H, SHAH A et al.: Phase I study of thematrix metalloproteinase inhibitor Bayer 12–9566. Proc. Am. Soc. Clin. Oncol (1998) 17:Abstract 840,217a.
   Google Scholar
• ROSEMURGY A, BUCKELS R, CHARNLEY R et al.: A randomised study comparing marimastat to gemcita-bine as first line therapy in patients with non-resectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:Abstract 1005, 261a.
   Google Scholar
• •The first randomised, controlled study of an MMPI in patients.
   Google Scholar
• TIERNEY G, STEELE R, GRIFFIN N et al: A pilot study ofthe effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur. J Cancer (1999) 35:563–568.
   PubMed Web of Science ®Google Scholar
• FIELDING JF, SCHOLEFIELD R, STUART R et al.: Ar andom-ised, double-blind, placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Soc. an. Oncol. (2000) 19:Abstract 929, 240a.
   Google Scholar
• ••The first placebo-controlled study and the most compellingevidence to date of a therapeutic effect for MMPIs in cancer patients.
   Google Scholar
• BRITISH BIOTECH PLC: Results of marimastat study 193in advanced pancreatic cancer. Press Release (2000) January 25.
   Google Scholar
• BRITISH BIOTECH PLC: Results of marimastat study 131in glioblastomamultiforme. Press Release (2000) June 23.
   Google Scholar
• Roche puts arthritis drug on hold. Scrip (2000) 2528:20.
   Google Scholar
• BROWN PD, BLOXIDGE RE, STUART NSA, GATTER KC,CARMICHAEL J: Correlation between expression of activated 72-kDa gelatinase and tumour spread in non-small cell lung carcinoma. J. Natl. Cancer Inst. (1993) 85:574–578.
   PubMed Web of Science ®Google Scholar
• AGOURON PHARMACEUTICALS INC: Agouron initiatespivotal trials of oral antiangiogenesis drug AG-3340 for treatment of lung cancer and prostate cancer. Press Release (1998) May 5.
   Google Scholar
• AGOURON PHARMACEUTICALS INC: Agouron announces pilot Phase II clinical trial of its matrix metalloproteinase inhibitor prinomastat in glioblas-toma multiforme. Press Release (1999) November 22.
   Google Scholar
• AETERNA INC: Aeterna has green light to begin PhaseIII trial of AE-941 /Neovastat in kidney cancer patients in the United States. Press Release (1999) March 9.
   Google Scholar
• CHIROSCIENCE PLC: Chiroscience presents update onstatus of MMPI research. Press Release (1998) June 23.
   Google Scholar
• COLLAGENEX PHARMACEUTICALS INC: CollaGenex reports findings from metastat clinical study. Press Release (1999) February 9.
   Google Scholar
• AGOURON PHARMACEUTICALS INC: Agouron initiatesPhase II study of oral anti-angiogenesis drug AG-3340 for treatment of age-related macular degeneration. Press Release (1998) September 15.
   Google Scholar
• PRIMROSE JN, BLEIBERG H, DANIEL F et al.: Pilot study oforal marimastat in recurrent colorectal cancer: an evaluation of biological activity by measurement of carcinoembryonic antigen. Br. J. Cancer (1999) 79:509–514.
   PubMed Web of Science ®Google Scholar
• WATSON SA, MORRIS TM, COLLINS HM, BAWDEN LJ, HAWKINS K, BONE EA: Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br. J. Cancer (1999) 81:19–23.
   PubMed Web of Science ®Google Scholar
• ONCOLOGY DRUGS ADVISORY COMMITTEE: Minutes from the 62nd Meeting. (1999) June 7
   Google Scholar
• •The conclusions from this meeting are likely to have a significant impact on the future development of tumouris-tatic agents.
   Google Scholar
• EARLY BREAST CANCER TRIALLISTS ' COLLABORATIVE GROUP: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (1998) 351:1451–1467.
   PubMed Web of Science ®Google Scholar